A phase 3, randomized, double-blind, placebo- and active-comparator-controlled clinical study of Adjuvant V940 (mRNA-4157) plus Pembrolizumab versus adjuvant placebo plus Pembrolizumab in participants with high-risk stage II-IV Melanoma (INTerpath-001)

Description

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT05933577 Opens a new window